There are five recognized types of lupus: systemic lupus erythematosus (SLE), cutaneous lupus, drug-induced lupus, neonatal lupus, and childhood-onset lupus. Each type affects the body differently, ranges from mild skin involvement to serious organ damage, and has its own triggers and outlook. An estimated 204,000 people in the United States have SLE alone, with 9 out of 10 being women.
Systemic Lupus Erythematosus (SLE)
SLE is the most common and most serious form. “Systemic” means it can affect nearly any organ in the body, including the joints, skin, kidneys, blood cells, brain, heart, and lungs. The immune system, which normally fights infections, turns against healthy tissue instead, causing widespread inflammation.
The hallmark sign is a butterfly-shaped rash across both cheeks and the bridge of the nose that worsens in sunlight. Beyond the rash, SLE can cause joint pain and swelling, extreme fatigue, fevers, chest pain when breathing deeply, and hair loss. Kidney damage is one of the most dangerous complications and remains a leading cause of death among people with lupus.
Women of childbearing age (15 to 44) face the highest risk. The outlook has improved dramatically over the past several decades. Five-year survival now sits around 96%, and 10-year survival exceeds 93%, up from less than 50% five-year survival in the 1950s. Most people with SLE manage the disease long-term with a combination of medications, including an antimalarial drug called hydroxychloroquine, which can reduce flares by as much as 50% and may help prevent the disease from spreading to the kidneys and brain.
Cutaneous (Skin) Lupus
Cutaneous lupus is limited to the skin. It can occur on its own in people who never develop SLE, though roughly 5% or more of those with cutaneous lupus will eventually progress to the systemic form. A skin biopsy is typically needed for diagnosis, since each subtype produces its own distinct pattern of lesions.
The three main subtypes are:
- Chronic cutaneous lupus (discoid lupus): The most common skin-only form. It produces thick, scaly, disc-shaped patches, usually on the face, ears, and scalp. These patches can cause permanent scarring and, on the scalp, irreversible hair loss.
- Subacute cutaneous lupus: Causes red, ring-shaped or scaly patches on sun-exposed areas like the arms, chest, and back. These lesions are strongly linked to sun sensitivity and typically don’t scar.
- Tumid lupus: A less common subtype that produces raised, smooth, reddish-purple plaques. It also tends to appear on sun-exposed skin and generally responds well to treatment.
Sun protection is a cornerstone of managing all forms of cutaneous lupus. Broad-spectrum sunscreen, protective clothing, and avoiding peak UV hours can significantly reduce flares.
Drug-Induced Lupus
Drug-induced lupus develops as a side effect of certain medications. It mimics many SLE symptoms, particularly joint pain, muscle aches, fatigue, and fever, but it rarely involves the kidneys or brain. The key difference is that symptoms typically disappear within days to weeks after stopping the medication that triggered them.
The medications most commonly linked to drug-induced lupus include hydralazine (a blood pressure drug), procainamide (a heart rhythm medication), isoniazid (used for tuberculosis), minocycline (an antibiotic), and a class of drugs called TNF-alpha inhibitors used for autoimmune conditions like rheumatoid arthritis. Not everyone who takes these medications will develop lupus-like symptoms. The risk depends on the specific drug, the dose, and how long you take it.
Because drug-induced lupus resolves on its own once the triggering medication is stopped, it carries the most favorable prognosis of all five types. If you develop unexplained joint pain, rash, or fatigue while on a long-term medication, this is worth raising with your doctor.
Neonatal Lupus
Neonatal lupus is a rare condition that affects newborns. It is not caused by the baby having lupus. Instead, it happens when certain antibodies in the mother’s blood, known as anti-SSA and anti-SSB antibodies, cross the placenta during pregnancy and temporarily affect the baby.
Most babies with neonatal lupus develop a mild skin rash and sometimes low blood cell counts or liver inflammation. These symptoms almost always resolve on their own within the first several months of life as the mother’s antibodies naturally clear from the baby’s system. The more serious concern is a heart rhythm problem called congenital heart block, where the electrical signals that control the baby’s heartbeat are permanently disrupted. This complication affects fewer than 2% of babies born to mothers who carry these antibodies, but when it does occur, some infants need a pacemaker.
Mothers who carry anti-SSA or anti-SSB antibodies may not have lupus themselves. These antibodies can also be present in women with Sjögren’s syndrome or in women with no autoimmune diagnosis at all. When the antibodies are detected, doctors can monitor the baby’s heart rhythm closely throughout pregnancy.
Childhood-Onset Lupus
Childhood-onset lupus is essentially SLE that appears before age 18, most often between ages 10 and 17. It involves the same immune system dysfunction as adult SLE, but it tends to be more aggressive. Children generally develop greater disease severity and accumulate organ damage earlier than adults diagnosed with the same condition.
Certain features show up more frequently in children than in adults with SLE: fever, swollen lymph nodes, kidney inflammation, inflammation around the heart, neuropsychiatric symptoms (such as seizures, mood changes, or difficulty concentrating), blood count abnormalities, and eye problems. Children diagnosed before age 10 tend to have the most severe disease activity and the poorest long-term outlook.
Treatment follows the same general approach as adult SLE, with hydroxychloroquine as a foundation alongside other immune-suppressing medications as needed. Because the disease starts so early, managing cumulative medication side effects and protecting growing organs becomes especially important over a lifetime of treatment.
How Lupus Is Diagnosed
Lupus is notoriously difficult to diagnose because its symptoms overlap with so many other conditions. There is no single blood test that confirms it. Instead, doctors use a combination of clinical signs, blood work, and sometimes biopsies.
The current classification system, developed jointly by European and American rheumatology organizations in 2019, uses a point-based approach. The entry requirement is a positive antinuclear antibody (ANA) test at a specific level. From there, points are assigned across seven clinical categories (such as skin, joints, kidneys, and blood) and three immune-related lab markers. A score of 10 or more points meets the threshold for an SLE classification. This system helps standardize diagnosis, but a skilled doctor can still diagnose lupus in someone who doesn’t neatly fit the scoring criteria.
For cutaneous lupus, a skin biopsy is the most direct route to diagnosis. For drug-induced lupus, the connection to a specific medication and the resolution of symptoms after stopping it are usually enough to confirm the diagnosis.
Who Is Most at Risk
Lupus disproportionately affects women. Of the estimated 204,000 Americans with SLE, about 184,000 are female and 20,000 are male. The peak window of risk is during the childbearing years, roughly ages 15 to 44. Hormonal factors, particularly estrogen, are thought to play a role in this disparity, though the exact mechanism isn’t fully understood.
Race and ethnicity also influence risk. Black, Hispanic, and Asian women develop lupus at higher rates and often experience more severe disease than white women. These disparities likely reflect a combination of genetic susceptibility, socioeconomic factors affecting access to early diagnosis and treatment, and differences in immune system biology that researchers are still working to untangle.